Semax has human studies, but they do not prove the popular nootropic claims.
Semax is a real seven-amino-acid peptide with animal research, small human imaging experiments, Russian-language clinical studies, and Russian registration reported by FDA. None of those facts automatically proves better focus, memory, mood, stroke recovery, or product safety. This guide shows exactly what each source can answer.
Human exposure exists. Proven cognitive enhancement does not.
Small healthy-volunteer studies found short-term resting-state brain-network differences after intranasal Semax. They did not show durable improvement in validated focus, memory, learning, productivity, symptoms, or daily function.
PubMed also indexes stroke and optic-nerve studies, but the English abstracts leave major questions about allocation, blinding, co-interventions, exact Semax form, effect size, and complete safety reporting. FDA judged the evidence insufficient for cerebral ischemia, migraine, and trigeminal neuralgia.
Read the Semax record in four fields.
This is a sourced status snapshot, not a safety score, treatment recommendation, or seller certification. Each field links back to the detailed record below.
Small human studies
Imaging and older clinical records exist, but key design and reporting details are incomplete.
Inspect the human evidenceNo proven nootropic benefit
The current studies do not establish durable focus, memory, learning, mood, or daily-function gains.
Audit the popular claimsNo FDA-approved US product
FDA reports Russian nasal-drop registration, which does not authorize a US product.
Check status and destination routesDated US price boards
Zero registry matches does not mean zero human studies
A trial registry and a publication database cover different records. The strongest answer checks both, then grades the study rather than counting search results.
Zero exact-name records
The July 21 exact-name ClinicalTrials.gov search returned no Semax records, including searches for ACTH(4-7)-PGP and MEHFPGP.
Repeat the registry search →Human publications still exist
PubMed and FDA still identify human Semax publications, including healthy-volunteer imaging and Russian-language clinical studies. Some are old, small, incompletely reported, or not registered in the US database.
Inspect the literature search →Do not let one database answer every question
Search registries and literature separately. Then grade the exact intervention, route, population, controls, endpoints, reporting quality, and product identity before drawing a conclusion.
Read the evidence method →Mechanism, imaging, clinical outcomes, and authorization are not interchangeable.
Every Semax claim should preserve the molecule, form, route, population, endpoint, comparison group, source language, and finished product.
Semax is a seven-amino-acid ACTH-fragment analogue
PubChem and FDA identify the Met-Glu-His-Phe-Pro-Gly-Pro sequence. FDA evaluates Semax free base and Semax acetate as different bulk drug substances and reports inconsistent naming, so a common-name label does not establish the exact form or finished product.
Most mechanism and neuroprotection claims begin in animals
Rat ischemia, gene-expression, neurotransmitter, and behavioral studies create plausible biological signals. They do not estimate benefit size, event rates, daily function, or long-term safety in people and cannot authenticate a seller product.
Small imaging studies measured brain-network changes
The cited human experiments measured resting-state fMRI shortly after intranasal Semax. A detectable imaging change can show pharmacologic activity, but it does not prove better memory, attention, mood, productivity, learning, or real-world performance.
Stroke and optic-nerve studies exist, with major transfer limits
PubMed indexes Russian-language controlled and comparative studies in stroke rehabilitation and optic-nerve disease. Allocation, blinding, co-interventions, exact Semax form, full safety reporting, and generalizability are not adequately resolved by the English abstracts.
Registered in Russia does not mean FDA approved
FDA reports that Semax is registered in Russia as nasal drops, while neither Semax free base nor acetate is a component of an FDA-approved drug. FDA staff proposed not adding either form to the 503A Bulks List, but PCAC recommended inclusion in separate 8-5-1 votes on July 24. Final FDA action remains pending.
What the Semax record shows, and what it cannot prove.
Each row puts the strongest relevant signal beside the inference that still fails.
Semax improves focus and memory
Small healthy-volunteer studies detected short-term resting-state fMRI and functional-connectivity differences after intranasal Semax.
Those studies did not establish durable improvement on validated attention, memory, learning, productivity, academic, occupational, or daily-function outcomes. A brain-image difference is not automatically a useful cognitive benefit.
Semax is a proven nootropic
Semax is described as a nootropic in parts of the literature and FDA reviewed nootropic claims within its cerebral-ischemia evidence assessment.
A category label and mechanism do not establish a clinically meaningful benefit. FDA concluded that the available evidence was insufficient for the reviewed uses and found no professional-society nootropic guideline.
Semax improves stroke recovery
PubMed indexes human stroke studies reporting neurological, motor, Barthel-index, and BDNF signals, while animal studies provide mechanistic support.
The human abstracts leave important questions about allocation, blinding, co-interventions, exact form, endpoint reporting, and safety. FDA judged the available cerebral-ischemia evidence insufficient and noted approved alternatives.
Semax treats migraine or trigeminal neuralgia
A small 1996 study evaluated one intranasal administration in twelve migraine participants and twenty-five participants with trigeminal neuralgia or dental plexalgia.
FDA found inadequate design and outcome detail, no convincing migraine effect, no benefit in typical trigeminal neuralgia, and insufficient evidence for either reviewed condition.
Semax has no important side effects
Most cited human references did not discuss adverse events. One small pain study reported none, while FDA found one consumer FAERS report involving ocular pain and burning after online nasal drops.
Sparse or absent reporting cannot establish safety or incidence. The report does not prove causality, identity, or product quality, and FDA also highlights bleeding, immunogenicity, aggregation, impurity, device, and route-specific uncertainties.
Semax and Selank are interchangeable
One healthy-volunteer imaging study included separate Semax, Selank, and placebo conditions and reported both shared and substance-specific connectivity findings.
The substances have different sequences, claimed uses, product records, and evidence. A shared study or a combination listing does not prove equivalence, compatibility, benefit, sterility, or safety.
Six records, six different questions.
This is not a vote count. A regulator synthesis, fMRI experiment, controlled clinical study, and rehabilitation subgroup analysis have different strengths and failure modes.
FDA effectiveness and safety synthesis
- Identity
- Often unclear whether free base or acetate
- Design
- Regulatory review of chemistry, literature, registries, safety, and proposed uses
- Participants
- Multiple small and heterogeneous references
FDA found human intranasal references but no human pharmacokinetic study, no subcutaneous safety data, and limited adverse-event reporting. It concluded that evidence was insufficient for cerebral ischemia, migraine, and trigeminal neuralgia.
Default-mode-network imaging study
- Identity
- Intranasal 1% Semax; free base or acetate not stated
- Design
- Semax versus placebo, resting-state fMRI before and shortly after administration
- Participants
- 24 healthy volunteers; 14 Semax, 10 placebo
The study reported a difference in default-mode-network topography. It did not measure a durable change in memory, attention, learning, productivity, symptoms, quality of life, or clinical function.
Semax, Selank, and placebo connectomic study
- Identity
- Semax and Selank studied separately; exact Semax form not stated
- Design
- Three-condition resting-state functional-connectivity experiment
- Participants
- 52 healthy participants across all conditions
The article reported group and condition differences in functional connectivity. FDA notes that the Semax participants may overlap with the earlier imaging study, so the two papers should not automatically be counted as independent treated cohorts.
Acute hemispheric ischemic-stroke study
- Identity
- Semax described as an ACTH(4-10) derivative; exact salt not stated
- Design
- Controlled comparative study added to conventional intensive therapy
- Participants
- 30 Semax-treated; 80 conventional-therapy controls
The abstract reports faster neurological recovery signals. It does not resolve randomization, blinding, complete baseline balance, co-intervention effects, adverse events, or whether the studied product matches a current US research vial.
Post-stroke rehabilitation and BDNF study
- Identity
- Semax regimen reported; exact free-base or acetate form not stated
- Design
- Early and late rehabilitation groups, each split into Semax-positive and Semax-negative subgroups
- Participants
- 110 post-stroke patients
The abstract reports BDNF, motor-performance, and Barthel-index associations. It does not describe blinded random allocation in the indexed abstract, so rehabilitation timing, selection, co-interventions, and other confounding cannot be excluded.
Optic-nerve disease comparative study
- Identity
- Semax route groups; exact free-base or acetate form not stated
- Design
- Intranasal drops, endonasal electrophoresis, and control alongside basic therapy
- Participants
- Group sizes not stated in the PubMed abstract
The abstract reports favorable visual-function changes, but does not provide group sizes, randomization, blinding, detailed effect estimates, or complete safety reporting. It cannot establish benefit for cognitive enhancement or a seller product.
US research listings are easier to find than decisive clinical evidence.
Availability and price are market observations, not medical validation. These figures describe dated exact-size seller pages and exclude shipping, coupons, checkout-only discounts, and unconfirmed rows from the in-stock range.
03
Three public US 10 mg research listings met the current comparison rules. Inclusion does not mean approval, recommendation, product authentication, provider certification, or lawful access in every destination.
Open every source row →03
All three carried an in-stock signal when checked. Stock can change and does not establish composition, concentration, sterility, fulfillment, import status, or suitability for use.
Check source freshness →$32.99-$50.00
The current range spans 52% from low to high before landed cost. Compare documentation access and source freshness beside price, then verify the exact product and seller.
Compare landed cost →Russian registration, FDA approval, and US compounding status are three separate records.
Country and product context must stay attached to every status statement.
FDA reports registered nasal drops
FDA's briefing says Semax is registered in Russia as 0.1% and 1% nasal drops. That is a foreign medicine-status fact, not evidence that a US research vial or compounded spray is the same product.
Read the cited FDA summary →No FDA-approved Semax product
FDA says neither Semax free base nor Semax acetate is a component of an FDA-approved drug. FDA staff proposed not adding either form to the 503A Bulks List.
Inspect the FDA review →PCAC recommended inclusion
Both form-specific questions received reported 8-5-1 votes. The committee advice is nonbinding and does not itself approve Semax or become the final FDA determination.
Open the verified vote record →Semax status and seller verification depend on the destination.
SAHPRA currently names Semax among illegally marketed unregistered peptide products in South Africa. FDA reports a registered nasal-drop product in Russia. Neither statement decides the exact product, prescription, compounding, import, seller, or supply-route status in every other country.
Twelve Semax questions, answered from the current record.
This is educational reporting, not medical advice, a prescription, emergency guidance, or a use protocol.
What is Semax peptide?
Semax is a synthetic seven-amino-acid peptide with sequence Met-Glu-His-Phe-Pro-Gly-Pro, also described as ACTH(4-7)-Pro-Gly-Pro or an ACTH(4-10) analogue. FDA evaluates Semax free base and Semax acetate as different bulk drug substances. A seller label using the short name does not establish which form is present, exact identity, concentration, purity, aggregation, sterility, device performance, or finished-product quality.
What does Semax do?
Laboratory and animal work links Semax to neurotrophin, neurotransmitter, inflammatory, and gene-expression pathways. Small human studies have detected short-term resting-state brain-network changes after intranasal administration. These signals show that Semax has been studied biologically, but they do not establish how much a person would improve, whether any change matters in daily life, or whether benefits outweigh product and treatment risks.
Does Semax improve focus or memory?
The cited record does not establish a dependable focus or memory benefit. Two publications report resting-state fMRI or functional-connectivity differences in healthy volunteers, but brain imaging was the outcome. They did not show durable improvement on validated memory, attention, learning, academic, occupational, productivity, or daily-function measures. FDA found insufficient evidence for the broader nootropic claim it reviewed within cerebral ischemia.
Is Semax a proven nootropic?
Semax is frequently called a nootropic in articles, seller pages, and historical use descriptions. That word is a category claim, not a result. FDA found no professional-society treatment guideline for a nootropic use and judged the available effectiveness evidence insufficient for cerebral ischemia, migraine, and trigeminal neuralgia. A mechanism, animal finding, small imaging signal, or foreign registration does not by itself prove meaningful cognitive enhancement.
Does Semax help stroke recovery?
Human stroke publications indexed by PubMed report neurological, motor, Barthel-index, and BDNF signals, and the preclinical record is extensive. Important design and reporting questions remain, including allocation, blinding, co-interventions, exact Semax form, full endpoint reporting, and safety. FDA reviewed the available cerebral-ischemia evidence and concluded it was insufficient. This page does not recommend replacing emergency stroke care, rehabilitation, or approved treatment.
Does Semax treat migraine or trigeminal neuralgia?
FDA found insufficient evidence for both conditions. The key small study included twelve people with migraine and twenty-five with trigeminal neuralgia or dental plexalgia, used a single intranasal administration, and had major limits in controls, blinding, outcome definition, and reporting. The agency reported no convincing migraine effect and no improvement in typical trigeminal neuralgia. A small subgroup signal cannot establish a treatment.
Why are there no Semax trials on ClinicalTrials.gov?
An exact ClinicalTrials.gov search returned no Semax record in the July 21 snapshot, but that database is not a complete index of every study ever conducted worldwide. PubMed indexes human Semax publications, and FDA reviewed additional papers and meeting abstracts, several from Russia. The correct conclusion is not that no human study exists. It is that registry coverage, publication coverage, study quality, and current product identity must be checked separately.
What are the side effects of Semax?
A reliable incidence table cannot be calculated from the cited evidence because most human references did not discuss adverse events and exact substance forms were often unclear. FDA found one consumer FAERS report describing ocular pain and burning after online nasal drops, but a spontaneous report cannot prove causality or product identity. FDA also highlights possible bleeding, immunogenicity, aggregation, impurity, device, and subcutaneous-route uncertainties.
Is Semax FDA approved?
No FDA-approved Semax drug is established by the cited FDA record. FDA states that neither Semax free base nor Semax acetate is a component of an FDA-approved drug. FDA staff proposed not adding either form to the 503A Bulks List, but PCAC recommended inclusion in separate 8-5-1 votes on July 24. The nonbinding committee advice is not final FDA action. FDA also reports that Semax is registered in Russia as nasal drops. Registration in one country does not create FDA approval, US compounding eligibility, or authorization in every other destination.
Semax vs Selank: are they the same?
No. Semax and Selank are different peptide sequences with different identities, evidence records, marketed claims, and product listings. A human imaging paper studied both in separate conditions, which does not make them interchangeable or establish a winner. A combined nasal product or seller bundle also does not prove formulation compatibility, delivered concentration, sterility, clinical benefit, or safety for either substance.
What is the correct Semax dosage?
There is no FDA-approved Semax label or established self-use dosage for the US research products discussed here. Historical Russian products, small intranasal studies, stroke protocols, animal experiments, seller pages, and clinic instructions involve different forms, concentrations, devices, populations, and purposes. They should not be converted into a personal regimen. This guide does not provide compounding, nasal preparation, injection, dosing, cycling, or stacking instructions.
Can you buy Semax legally where you live?
A visible seller page or shipping claim cannot decide that. The answer depends on the exact product, intended use, medicine authorization, compounding rules, prescription controls, import route, pharmacy status, and destination. SAHPRA currently names Semax among illegally marketed unregistered peptides in South Africa. That record is important locally but does not decide another country. Use the linked country and regulator routes before interpreting an offer.
A biological signal is not a finished product or a personal decision.
Semax free base, Semax acetate, a historical Russian nasal-drop product, a study intervention, compounded spray, subcutaneous preparation, seller vial, and combination with Selank can differ in identity, concentration, formulation, device, impurities, exposure, and risk.
FDA approval, Russian registration, 503A list status, country access, seller availability, documentation, product authentication, and individual medical care are separate records. None substitutes for emergency stroke treatment or supplies a personal regimen.